1. Use of an effective amount of an alkalizing agent that increases the intracellular pH of a host cell and/or of an intracellular compartment of a host cell and an effective amount of a bactericidal agent in the manufacture of a medicament for the treatment of a bacterial infection in a subject in need thereof, wherein the bactericidal agent is selected from the group consisting of a subclass IIIa bacteriocin, a bacterial autolysin and a bacteriophage lysin, and wherein the agent that increases the intracellular pH and/or the pH of the intracellular compartment is a lysosomotropic alkalizing agent.

2. The use according to claim 1, wherein the bacterial infection is an intracellular and/or persistent bacterial infection and/or is a *Staphylococcus* infection, preferably an *S. aureus* infection.

3. The use according to claim 1 or 2, wherein the host cell is a eukaryotic host cell within the subject in need of treatment and/or wherein the intracellular compartment is a phagolysosome.

4. The use according to any of the preceding claims, wherein the lysosomotropic alkalizing agent is selected from the group of chloroquine, bafilomycin A1, and ammonium chloride.

5. The use according to any of the preceding claims, wherein the bactericidal agent is a bactericidal agent capable of entering the host cell and/or the intracellular compartment of the host cell.

6. The use according to claim 1 to 5, wherein the bactericidal agent comprises a functional enzymatic domain from a cell wall lytic enzyme and preferably further comprises a protein transduction domain.

7. The use according to claim 6, wherein the bactericidal agent further comprises an antimicrobial peptide.

8. The use according to claim 6 or 7, wherein the bactericidal agent further comprises a cell wall binding domain.

9. The use according to claim 6 - 9, wherein the protein transduction domain is selected from the group consisting of SEQ ID NO: 12 - 25.

10. The use according to claim 6 - 9, wherein the functional enzymatic domain from a cell wall lytic enzyme is selected from the group consisting of SEQ ID NO: 1 - 7.

11. The use according to claim 8 - 10, wherein the cell wall binding domain is selected from the group consisting of SEQ ID NO: 8 - 11.

12. The use according to claim 7 - 11, wherein the antimicrobial peptide is selected from the group consisting of SEQ ID NO: 70 - 90.